Thread: Prothena Phase 1B study of Alpha Synuclein and Parkinsons! Yeah!
View Single Post
Old 04-02-2017, 09:52 PM
jeffreyn jeffreyn is offline
Member
  
Join Date: Apr 2016
Location: Australia
Posts: 352
8 yr Member
jeffreyn jeffreyn is offline
Member
 
Join Date: Apr 2016
Location: Australia
Posts: 352
8 yr Member
Default Hot off the presses!
... and here is a link to the just-announced results of the multiple-ascending-dose (MAD) trial:

Clinical Results Presented from Prothena's Phase 1b Study of PRX2/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease (NASDAQ:PRTA)

Quick summary:
- the Phase 1 trials were successful;
- a global Phase 2 trial of approximately 300 patients with early PD is planned to commence in the second quarter of 2017.
Last edited by jeffreyn; 04-03-2017 at 06:11 AM. Reason: Added summary
jeffreyn is offline   Reply With QuoteReply With Quote